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ABSTRACT
Background: Refugees are disproportionately affected by latent
tuberculosis infection (LTBI) and active tuberculosis (TB) compared
to the general US population. More than 50% of TB cases in the
US occur in foreign-born persons. In addition, approximately 80%
of TB cases in the US are a result of reactivation of LTBI.
Treatment of LTBI is effective to prevent and control TB.
Unfortunately, LTBI treatment completion rates in the foreign-born
are less than 50%. Methods: After conducting a retrospective chart
review to establish baseline rates of treatment completion in our
LTBI refugee patients, we implemented a model of prospective
chart review, initial face-to-face counseling, phone follow up and
community monitoring with pharmacy serving as a central point of
contact for model coordination and execution. Results: Our LTBI
treatment completion rate is now 64% (23 out of 36 LTBI refugee
patients), representing an almost 2-fold improvement over our
baseline rate of 33%.

INTRODUCTION
The majority of cases (80%) of active tuberculosis (TB) cases in
the United States result from reactivation of latent TB infection
(LTBI).1 In addition, greater than 50% of active TB cases in the
United States occur in foreign-born individuals.2
Approximately 80,000 refugees resettled in the U.S. annually and
as such cities with large refugee populations can have higher than
national average rates of TB.3 While the diagnosis and treatment of
LTBI is an effective method for reducing cases of active TB, the
national rate of LTBI completion among foreign-born in the U.S. is
less than 50%.4
To establish baseline rates of LTBI incidence and treatment
completion for our refugee population, the Jefferson Center for
Refugee Health conducted a retrospective chart review for the
time period of 2007-2011. We found that 23.1% of incoming
patients to the center had LTBI and among patients started on
treatment 33.1% completed therapy.
Using these baseline rates as a foundation, we developed an
interdisciplinary model consisting of pharmacy, medicine, nursing,
and social work to improve LTBI completion rates in our refugee
patients.

METHODS
Visit #

RESULTS

Description
Blood Work

Process
Quantiferon-TB Gold

(Resettlement Agency)
-1

Prospective Chart Review
(Medicine/Pharmacy)

Initial Refugee Visit
(Medicine/Pharmacy/
Nursing/Social Work)
0

Follow-Up Refugee Visit
(Medicine/Pharmacy/
Nursing/Social Work)
1

Phone
Call

2 weeks after Visit #1
Beginning of month 2 of
treatment

Phone
Call

Phone
Call
Phone
call
Phone
call

Quantiferon-TB Gold, CXR
Quantiferon-TB Gold Results
•If Neg Quant: no further f/u, If Indeterminate PPD placed (nursing visit for read)
•If Pos Quant: CXR ordered
oIf Neg CXR: LTBI treatment to begin at 1 mo f/u visit
oIf Pos CXR: Sputum sample
 If Neg Sputum sample: LTBI treatment to begin at 1 mo f/u visit
(scheduled by social work)
 If Pos Sputum sample: refer to Phila Dept of Health (Active TB)

LTBI Treatment Initiated
•Rifampin (Rif) 10mg/kg/day (max 600mg QD) x 4 mos; completion=120 doses within
6 mos.
•Isoniazid (INH) 5mg/kg/day (max 300mg QD) x 6-9 mos; completion: 6 mos
regimen=180 doses within 9 mos;9 mos=270 doses within 12 mos.
Face-to-Face Patient Education (Pharmacy/Medicine)
•Power point presentation of how to have a prescription filled in the U.S.
•Importance of taking medication, what to expect, when to call the HCP
•Reinforce education with written material in native language or pictorial material as
appropriate (will depend on literacy)

Pharmacy contacts local pharmacy to confirm refills:
•If no refill noted at pharmacy outbound call to patient to assess
•If refill noted, documented in tracking sheet, then outbound call to patient to assess
tolerance
•If any other issues identified , pharmacy notifies medicine, nursing or social work as
appropriate

Pharmacy repeats procedure described above

Beginning month 3 of
treatment

Pharmacy repeats procedure described above

Beginning of month 4 of
treatment

Pharmacy repeats procedure described above

Patient Counseling Guide:

Phone
call

Diagnosed

Started on
LTBI Treatment

Completed
Treatment

Incomplete
Treatment

Lost to
Follow-up

47*

36

23

6

7

* 11 patients diagnosed but lost to follow-up prior to initiating treatment
• LTBI incidence rate: 21.8%
• LTBI treatment completion rate: 63.8%
Demographics of Patient Who Completed (n=23)
Gender
n (%)
• Female: 14 (61)
• Male: 9 (39)

Follow up phone call to patient to assess tolerance, symptoms, adherence, answer
any questions patient may have

Beginning month 3 of
treatment

End of month 4 of
treatment

For the time period 9/1/2012 thru 6/7/2013
• Total number of new patient visits: 215

Age
(mean, years)
41

Country of Origin
n (%)
•
•
•
•

Bhutan: 16 (70)
Iraq: 4 (17)
Eritrea: 1 (4)
Myanmar: 2 (9)

CONCLUSION
Our model increased treatment completion rates significantly in our
refugee patients. A key limitation to the model was the low success
rate of reaching patients via outbound calls placed after treatment
initiation; reasons for this are multifactorial and include patient
relocation as well patients’ varied work schedules. However, we
found using pharmacy refill history as a surrogate marker of
completion an efficient way to capture treatment completion rates.

Pharmacy contacts local pharmacy to confirm refills:
•If no refill noted, outbound call to patient to assess
•If refill noted, completion document in patient chart

REFERENCES
1.Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011 Apr
14;364(15):1441-8.
2.Trends in Tuberculosis, 2012. Available at: http://www.cdc.gov/tb/publications/factsheets/statistics/TBTrends.htm.
Accessed October 1, 2013.
3.Guidelines for Screening for Tuberculosis Infection and Disease during the Domestic Medical Examination for Newly
Arrived Refugees. Available at: http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/tuberculosisguidelines.html. Accessed October 1, 2013.
4.Horsburgh CR Jr, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance and completion in the United
States and Canada. Chest. 2010 Feb;137(2):401-9.

ACKNOWLEDGEMENTS
The authors gratefully acknowledge the following individuals for their contributions in the development, delivery of care,
and data collection for this model: Elizabeth Bates, Abbie Santana, Colleen Payton, Rayelle Walters, Rebecca Buckler,
Sang-weon Lee, Elizabeth Mearns, Laura Williams, Theresa Zelman, Ji Chung, Stephanie Komura, Jeehna Park.

